| MeSH term | MeSH ID | Detail |
|---|---|---|
| Neurotoxicity Syndromes | D020258 | 34 associated lipids |
| Autoimmune Diseases of the Nervous System | D020274 | 1 associated lipids |
| Migraine with Aura | D020325 | 1 associated lipids |
| Hypertensive Encephalopathy | D020343 | 1 associated lipids |
| Paraneoplastic Syndromes, Nervous System | D020361 | 1 associated lipids |
| Osteoarthritis, Knee | D020370 | 13 associated lipids |
| Sciatic Neuropathy | D020426 | 13 associated lipids |
| Peroneal Neuropathies | D020427 | 1 associated lipids |
| Brain Infarction | D020520 | 17 associated lipids |
| Stroke | D020521 | 32 associated lipids |
| Nervous System Autoimmune Disease, Experimental | D020721 | 3 associated lipids |
| Parkinsonian Disorders | D020734 | 20 associated lipids |
| Intracranial Thrombosis | D020767 | 2 associated lipids |
| Central Nervous System Viral Diseases | D020805 | 1 associated lipids |
| Hypoxia-Ischemia, Brain | D020925 | 22 associated lipids |
| Neuroaspergillosis | D020953 | 2 associated lipids |
| Brachial Plexus Neuritis | D020968 | 2 associated lipids |
| Lacerations | D022125 | 1 associated lipids |
| Coronary Stenosis | D023921 | 6 associated lipids |
| Polyomavirus Infections | D027601 | 1 associated lipids |
| Pulmonary Disease, Chronic Obstructive | D029424 | 16 associated lipids |
| Denys-Drash Syndrome | D030321 | 1 associated lipids |
| Papillomavirus Infections | D030361 | 4 associated lipids |
| Hyperuricemia | D033461 | 4 associated lipids |
| Hypoalbuminemia | D034141 | 1 associated lipids |
| Mastocytosis, Cutaneous | D034701 | 1 associated lipids |
| Cholecystolithiasis | D041761 | 2 associated lipids |
| Intestinal Volvulus | D045822 | 1 associated lipids |
| Ileus | D045823 | 3 associated lipids |
| Coproporphyria, Hereditary | D046349 | 1 associated lipids |
| Protoporphyria, Erythropoietic | D046351 | 1 associated lipids |
| Colitis, Collagenous | D046729 | 1 associated lipids |
| Hepatic Insufficiency | D048550 | 1 associated lipids |
| Diabetes Complications | D048909 | 4 associated lipids |
| Dyslipidemias | D050171 | 7 associated lipids |
| Atherosclerosis | D050197 | 85 associated lipids |
| Granulomatosis, Orofacial | D051261 | 2 associated lipids |
| Lymphohistiocytosis, Hemophagocytic | D051359 | 1 associated lipids |
| Renal Insufficiency | D051437 | 8 associated lipids |
| Delayed Graft Function | D051799 | 2 associated lipids |
| Nocturia | D053158 | 1 associated lipids |
| Dysuria | D053159 | 1 associated lipids |
| Posterior Leukoencephalopathy Syndrome | D054038 | 1 associated lipids |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | D054198 | 10 associated lipids |
| Dendritic Cell Sarcoma, Interdigitating | D054739 | 1 associated lipids |
| Idiopathic Interstitial Pneumonias | D054988 | 1 associated lipids |
| Primary Graft Dysfunction | D055031 | 1 associated lipids |
| Failed Back Surgery Syndrome | D055111 | 3 associated lipids |
| Pancreatitis, Graft | D055589 | 1 associated lipids |
| Multiple Pulmonary Nodules | D055613 | 2 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Friob MC et al. | A combined HPLC-ELISA evaluation of FK 506 in transplant patients. | 1991 | Transplant. Proc. | pmid:1721265 |
| Machida M et al. | Effect of temperature and hematocrit on plasma concentration of FK 506. | 1991 | Transplant. Proc. | pmid:1721266 |
| Kawauchi M et al. | Plasma level of FK 506 in newborn goats and infant baboons. | 1991 | Transplant. Proc. | pmid:1721267 |
| Iwasaki K et al. | Pharmacokinetic study of FK 506 in the rat. | 1991 | Transplant. Proc. | pmid:1721268 |
| Tanida I et al. | Yeast cyclophilin-related gene encodes a nonessential second peptidyl-prolyl cis-trans isomerase associated with the secretory pathway. | 1991 | Transplant. Proc. | pmid:1721297 |
| O'Neill EA et al. | The FK 506-sensitive nature of the interleukin-2 promoter is derived from a specific array of multiple regulatory elements. | 1991 | Transplant. Proc. | pmid:1721298 |
| Nelson PA et al. | Effect of immunosuppressive drugs on cytokine gene transcription studied by message amplification phenotyping (MAPPing) polymerase chain reaction. | 1991 | Transplant. Proc. | pmid:1721299 |
| Dumont FJ et al. | Up-regulation of gene expression by FK 506. | 1991 | Transplant. Proc. | pmid:1721300 |
| Hultsch T and Hohman RJ | Categorizing receptor-signaling pathways with FK 506 and rapamycin. | 1991 | Transplant. Proc. | pmid:1721328 |
| Takai K et al. | Immunosuppressive effects of FK 506 on rat lymphoid organs. | 1991 | Transplant. Proc. | pmid:1721329 |
| Ishibashi M et al. | Effect of FK 506 on generation of activated macrophages invading rejected skin allografts in rats: discrepancy of in vitro versus in vivo effects. | 1991 | Transplant. Proc. | pmid:1721330 |
| Kawauchi M et al. | Flow cytometric analysis of lymphocyte populations in FK 506-treated newborn goats. | 1991 | Transplant. Proc. | pmid:1721331 |
| Shapiro R et al. | FK 506 in clinical kidney transplantation. | 1991 | Transplant. Proc. | pmid:1721361 |
| Todo S et al. | One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. | 1991 | Transplant. Proc. | pmid:1703340 |
| McCauley J et al. | Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome. | 1991 | Transplant. Proc. | pmid:1721362 |
| Zeevi A et al. | Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection. | 1991 | Transplant. Proc. | pmid:1703341 |
| Japanese study of FK 506 on kidney transplantation: results of an early phase II study. Japanese FK 506 Study Group. | 1991 | Transplant. Proc. | pmid:1721363 | |
| van Hoek B et al. | Recurrence of ductopenic rejection in liver allografts after retransplantation for vanishing bile duct syndrome. | 1991 | Transplant. Proc. | pmid:1703343 |
| Jensen CW et al. | Pediatric renal transplantation under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721364 |
| McCauley J et al. | The question of FK 506 nephrotoxicity after liver transplantation. | 1991 | Transplant. Proc. | pmid:1703344 |
| Carroll PB et al. | Synexin: a target protein for toxic effects of cyclosporine and FK 506 in endocrine cells. | 1991 | Transplant. Proc. | pmid:1721394 |
| Scantlebury V et al. | New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. | 1991 | Transplant. Proc. | pmid:1721395 |
| Carroll PB et al. | FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication. | 1991 | Transplant. Proc. | pmid:1721396 |
| Freise CE et al. | Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient. | 1991 | Transplant. Proc. | pmid:1721397 |
| Murase N et al. | Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. | 1991 | Transplant. Proc. | pmid:1721424 |
| Langrehr JM et al. | Indefinite small bowel allograft survival after limited immunosuppressive therapy is not due to specific hyporesponsiveness. | 1991 | Transplant. Proc. | pmid:1721425 |
| Takeda Y et al. | Effect of FK 506 on the survival of rat small bowel allografts. | 1991 | Transplant. Proc. | pmid:1721426 |
| Griffiths EJ and Halestrap AP | Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. | 1991 | Biochem. J. | pmid:1706598 |
| Fukuzawa M et al. | Effect of donor-specific transfusion and FK 506 on small intestine allotransplantation. | 1991 | Transplant. Proc. | pmid:1721427 |
| Brabletz T et al. | The immunosuppressives FK 506 and cyclosporin A inhibit the generation of protein factors binding to the two purine boxes of the interleukin 2 enhancer. | 1991 | Nucleic Acids Res. | pmid:1707162 |
| Iwaki Y et al. | Replacement of donor lymphoid tissue in small-bowel transplants. | 1991 | Lancet | pmid:1707470 |
| Markus PM et al. | Effects of in vivo treatment with FK506 on natural killer cells in rats. | 1991 | Transplantation | pmid:1707562 |
| Mochizuki M et al. | A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis. | 1991 | Transplant. Proc. | pmid:1721456 |
| Roat MI et al. | Treatment of Cogan's syndrome with FK 506: a case report. | 1991 | Transplant. Proc. | pmid:1721457 |
| Carroll PB et al. | The use of FK 506 in new-onset type I diabetes in man. | 1991 | Transplant. Proc. | pmid:1721458 |
| McCauley J et al. | FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. | 1991 | Transplant. Proc. | pmid:1721459 |
| Banerji SS et al. | The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. | 1991 | Mol. Cell. Biol. | pmid:1712901 |
| Markus PM et al. | FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. | 1991 | Surgery | pmid:1713358 |
| Farley DE et al. | The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. | 1991 | Transplantation | pmid:1713360 |
| Vathsala A et al. | The immunosuppressive antagonism of low doses of FK506 and cyclosporine. | 1991 | Transplantation | pmid:1713361 |
| Sakr MF et al. | Protective effect of FK 506 against hepatic ischemia in rats. | 1991 | Transplant. Proc. | pmid:1703689 |
| Katayama Y et al. | Immunosuppressive effects of FK 506 and 15-deoxyspergualin in rat lung transplantation. | 1991 | Transplant. Proc. | pmid:1703690 |
| Thomson AW | The immunosuppressive macrolides FK-506 and rapamycin. | 1991 | Immunol. Lett. | pmid:1717376 |
| Takaya S et al. | Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1703691 |
| Nakahama H et al. | Comparative effects of cyclosporine A and FK-506 on endothelin secretion by a cultured renal cell line, LLC-PK1. | 1991 | J. Cardiovasc. Pharmacol. | pmid:1725322 |
| Steeves M et al. | In-vitro interaction of a novel immunosuppressant, FK 506, and antacids. | 1991 | J. Pharm. Pharmacol. | pmid:1717676 |
| Hildebrandt A et al. | FK 506: short- and long-term treatment after cardiac transplantation in nonhuman primates. | 1991 | Transplant. Proc. | pmid:1703694 |
| Romanowski P et al. | [Synthetic immunomodulators designed on the basis of natural products of microorganisms]. | 1991 | Postepy Biochem. | pmid:1725924 |
| Altmeyer A et al. | Unexpected up-regulation of gene expression by cyclosporin A and FK-506 in a T-cell lymphoma: both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin. | 1991 | Int. J. Immunopharmacol. | pmid:1726093 |
| Gordon RD et al. | Liver transplantation at the University of Pittsburgh, 1984 to 1990. | 1991 | Clin Transpl | pmid:1726458 |